Characteristics | Overall |
N (%) | 165 (100) |
Male (%) | 121 (73.3) |
Training: interventionalist (%) | 84 (50.9) |
Geography (%) | |
North America | 23 (13.9) |
South America | 2 (1.2) |
Europe | 112 (67.9) |
Africa | 1 (0.6) |
Middle East | 2 (1.2) |
Asia | 10 (6.1) |
Australia | 15 (9.1) |
Appointment level (%) | |
Junior | 11 (6.7) |
Mid-career | 28 (17.0) |
Senior | 126 (76.4) |
Annual mechanical thrombectomy volume (%) | |
<100 | 50 (30.3) |
100–200 | 66 (40.0) |
>200–300 | 29 (17.6) |
>300 | 20 (12.1) |
Dedicated stroke patient care time (%) | |
<10% | 10 (6.1) |
10–50% | 77 (46.7) |
51–99% | 63 (38.2) |
100% | 15 (9.1) |
Acceptable uncertainty margin (%), median (IQR)) | 3 (1–5) |
Trial participation (%) | |
IVT vs placebo: yes (%) | 42 (25.5) |
MT+IVT vs IVT: yes (%) | 51 (30.9) |
MT vs MT +IVT= :yes (%) | 51 (30.9) |
In patients undergoing MT do you stop IVT before full dose is administered? (%) | |
No, unless there are clear medical reasons (eg, angiographic signs of bleeding) | 102 (61.8) |
Yes, as a standard procedure at first device deployment | 16 (9.7) |
Yes, as a standard procedure after successful reperfusion is reached | 7 (4.2) |
Yes, on an individual case basis after successful reperfusion is reached | 31 (18.8) |
Other | 9 (5.5) |
Data are displayed as n (%), and median (IQR).
IVT, intravenous thrombolysis; MT, mechanical thrombectomy.